Most patients with treatment-resistant depression reported positive experiences with esketamine nasal spray. In a survey of 236 outpatients, 88.4% reported enhanced quality of life. Satisfaction levels varied: 10.2% were unsatisfied, 19.1% partially satisfied, 44.4% satisfied, and 26.3% very satisfied. The most satisfied patients noted early improvements in depressed mood, suicidal thoughts, and restlessness, and reported functional gains across all domains. Artificial intelligence analysis of open-ended responses identified themes of personal growth and a desire for tailored treatment settings. Integrating patient-reported experiences may help personalize care and improve adherence.
A review of native medicinal plants from Latin America and the Caribbean (LAC) identified 12 species from 10 families traditionally used to manage substance use disorders (SUDs). These plants, including Banisteriopsis caapi and Hypericum perforatum, may work through mechanisms such as GABergic activity, opioid receptor interaction, neurotransmitter modulation, NMDA receptor antagonism, antioxidant/anti-inflammatory effects, or enhancement of neuroplasticity. Preclinical and clinical studies suggest these plants can curb cravings and mitigate withdrawal symptoms. However, clinical validation remains limited, revealing a gap between traditional use and scientific evidence.